(24/7 MARKET NEWS) invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited (HKEX 1177 HK), and F-star Therapeutics, Inc. (NASDAQ:FSTX), stated that the two companies entered into a definitive agreement whereby invoX will acquire all of F-star’s issued and outstanding common stock for $7.12 per share, which values F-star at approximately $161 million. The transaction received unanimous approval by the Boards of Directors, of both companies, and is expected to close in the second half of 2022.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.